Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNFerade and Dendritic Cell Vaccine for Unresectable Pancreatic Cancer
NCT00868114Phase 2Terminated
- Sponsor
- Leo W. Jenkins Cancer Center
- Start
- Jul 2006
- Primary completion
- Jul 2013
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of golnerminogene pradenovec in pancreatic cancer (PC), sponsored by Leo W. Jenkins Cancer Center. Started Jul 2006; status: terminated.
02
Drugs
golnerminogene pradenovec
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00868114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00868114.